Soluble guanylate cyclase modulation in heart failure and chronic kidney disease: mechanisms, clinical evidence, and translational boundaries
- 1Department of Cardiology, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing , ,
Abstract
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist and amplify one another through hemodynamic, neurohormonal, inflammatory, oxidative, and microvascular mechanisms. Impaired nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP)–protein kinase G (PKG) signaling represents a biologically plausible component of this cardiorenal interaction. However, clinical translation of sGC modulation requires careful interpretation because sGC stimulators and activators preferentially engage distinct biochemical states of the enzyme, and available evidence remains heterogeneous across compounds, phenotypes, and endpoint domains. This narrative review integrates mechanistic, preclinical, and clinical evidence for clinically evaluated sGC modulators, including vericiguat, riociguat, praliciguat, runcaciguat, avenciguat, and cinaciguat, with emphasis on HF–CKD translational relevance. Vericiguat demonstrated benefit in a specific population of clinically stabilized patients with symptomatic chronic HF, LVEF below 45%, and a recent worsening-HF event. In VICTORIA, the reduction in the composite endpoint of cardiovascular death or first HF hospitalization was primarily driven by fewer HF hospitalizations, with no statistically significant reduction in cardiovascular death alone. Conversely, the VICTOR trial was neutral for its primary endpoint in stable ambulatory HFrEF, and HFpEF studies of vericiguat or praliciguat did not improve their prespecified biomarker, health-status, or exercise endpoints. In CKD populations, runcaciguat and avenciguat have shown short-term albuminuria reductions, but these surrogate signals have not established durable kidney protection, including long-term preservation of eGFR or prevention of kidney failure. To contextualize heterogeneous evidence, we propose an evidence-interpretation framework incorporating HF phenotype and clinical state, CKD phenotype, putative sGC redox biology, and endpoint domain. This framework is intended for evidence interpretation and hypothesis generation rather than patient-level treatment selection; no validated clinical assay defines tissue sGC redox state, and no prospective treatment-by-biomarker interaction has established redox-guided selection. Future studies should prioritize phenotype-enriched HF–CKD populations, contemporary background therapy, and prespecified cardiovascular and kidney outcomes to define the clinical role of sGC modulation.
Related
- Descending Pain Modulation Across Pain States: Circuit Mechanisms, Neurochemical Plasticity, and Translational Perspectives
- VAMP5 Mediates Sevoflurane-Induced Immune Modulation in Cervical Cancer: A Clinical Translational Study.
- Herbal-derived bioactive compounds in stroke recovery: from neuroprotective mechanisms to clinical evidence and translational challenges
- Stem Cell-Based Therapies in Companion Animals: Molecular Mechanisms, Clinical Applications, and Translational Perspectives
- Antibody–drug conjugates and immunogenic cell death in breast cancer: agent-specific mechanisms, clinical evidence and translational priorities
BibTeX
@article{yuan2026soluble,
title = {{Soluble guanylate cyclase modulation in heart failure and chronic kidney disease: mechanisms, clinical evidence, and translational boundaries}},
author = {Wenhui Yuan and Bo Zhou and Changqing Yu},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1954549},
url = {https://europepmc.org/article/PMC/PMC13668576},
note = {CC BY},
}
RIS
TY - JOUR
TI - Soluble guanylate cyclase modulation in heart failure and chronic kidney disease: mechanisms, clinical evidence, and translational boundaries
AU - Wenhui Yuan
AU - Bo Zhou
AU - Changqing Yu
PY - 2026
DA - 2026/10/01
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1954549
UR - https://europepmc.org/article/PMC/PMC13668576
AB - Heart failure (HF) and chronic kidney disease (CKD) frequently coexist and amplify one another through hemodynamic, neurohormonal, inflammatory, oxidative, and microvascular mechanisms. Impaired nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP)–protein kinase G (PKG) signaling represents a biologically plausible component of this cardiorenal interaction. However, clinical translation of sGC modulation requires careful interpretation because sGC stimulators and activators preferentially engage distinct biochemical states of the enzyme, and available evidence remains heterogeneous across compounds, phenotypes, and endpoint domains. This narrative review integrates mechanistic, preclinical, and clinical evidence for clinically evaluated sGC modulators, including vericiguat, riociguat, praliciguat, runcaciguat, avenciguat, and cinaciguat, with emphasis on HF–CKD translational relevance. Vericiguat demonstrated benefit in a specific population of clinically stabilized patients with symptomatic chronic HF, LVEF below 45%, and a recent worsening-HF event. In VICTORIA, the reduction in the composite endpoint of cardiovascular death or first HF hospitalization was primarily driven by fewer HF hospitalizations, with no statistically significant reduction in cardiovascular death alone. Conversely, the VICTOR trial was neutral for its primary endpoint in stable ambulatory HFrEF, and HFpEF studies of vericiguat or praliciguat did not improve their prespecified biomarker, health-status, or exercise endpoints. In CKD populations, runcaciguat and avenciguat have shown short-term albuminuria reductions, but these surrogate signals have not established durable kidney protection, including long-term preservation of eGFR or prevention of kidney failure. To contextualize heterogeneous evidence, we propose an evidence-interpretation framework incorporating HF phenotype and clinical state, CKD phenotype, putative sGC redox biology, and endpoint domain. This framework is intended for evidence interpretation and hypothesis generation rather than patient-level treatment selection; no validated clinical assay defines tissue sGC redox state, and no prospective treatment-by-biomarker interaction has established redox-guided selection. Future studies should prioritize phenotype-enriched HF–CKD populations, contemporary background therapy, and prespecified cardiovascular and kidney outcomes to define the clinical role of sGC modulation.
SN - 1663-9812
ER -